On October 30, 2019 Veracyte, Inc. (Nasdaq: VCYT) reported that new data advancing the understanding of genomic alterations – specifically, NTRK, RET, BRAF and ALK fusions – that are targeted by new precision medicine therapies for thyroid cancer will be presented at the 89th Annual Meeting of the American Thyroid Association, which will be held October 30-November 3, 2019 in Chicago (Press release, Veracyte, OCT 30, 2019, View Source [SID1234550046]). The findings will be presented in three posters and are derived from Afirma Xpression Atlas testing of Veracyte’s extensive biorepository of fine needle aspiration (FNA) samples from patients undergoing evaluation for thyroid cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We believe our extensive collection of thyroid nodule FNA samples with RNA whole-transcriptome sequencing data uniquely enables us to broaden the scientific understanding of the role of key gene alterations in thyroid cancer," said Richard T. Kloos, M.D., senior medical director, endocrinology, at Veracyte. "Moreover, as the role of precision medicine in thyroid cancer treatment expands, our Afirma Xpression Atlas helps inform physicians’ treatment decisions for their patients with thyroid cancer using the same minimally invasive sample that is used for initial diagnosis with the Afirma Genomic Sequencing Classifier."

Following are details of the presentations, which will be presented in the Sheraton Grand Chicago Exhibit Hall:

Title:

Positive Predictive Value of NTRK, RET, BRAF and ALK Fusions in Bethesda III/IV Thyroid Fine-Needle Aspirates

Presenter:

Brendan C. Stack, M.D., University of Arkansas for Medical Sciences

Date/Time:

Friday, Nov. 1, 10:05 a.m.-11:00 a.m. and 12:15 p.m.-1:30 p.m. (Central Time)

Poster #:

Short Call Poster 55

Title:

Identification of Rare, Canonically Mutually Exclusive Variants in Thyroid FNAs

Presenter:

Bryan R. Haugen, M.D., University of Colorado School of Medicine

Date/Time:

Saturday, Nov. 2, 10:05 a.m.-11:00 a.m. and 11:45 a.m.-1:00 p.m. (Central Time)

Poster #

461

Title:

NTRK, RET, BRAF and ALK Fusions in Thyroid Fine-Needle Aspirates (FNAs)

Presenter:

Mimi I. Hu, M.D., University of Texas, M.D. Anderson Cancer Center

Date/Time:

Saturday, Nov. 2, 10:05 a.m.-11:00 a.m. and 11:45 a.m.-1:00 p.m. (Central Time)

Poster #

462

On October 30, 2019 RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, reported the pricing of its initial public offering of 3,000,000 shares of common stock at a public offering price of $12.00 per share (Press release, RAPT Therapeutics, OCT 30, 2019, View Source [SID1234550062]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition, the underwriters have been granted a 30-day option to purchase up to an additional 450,000 shares of common stock at the initial public offering price, less the underwriting discount. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by RAPT, are expected to be $36.0 million, excluding any exercise of the underwriters’ option to purchase additional shares. The shares are expected to begin trading on the Nasdaq Global Market on October 31, 2019, under the ticker symbol "RAPT." The offering is expected to close on November 4, 2019, subject to the satisfaction of customary closing conditions.

BMO Capital Markets, Wells Fargo Securities and UBS Investment Bank are acting as joint book-running managers for the offering.

The offering is being made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained, when available, from: BMO Capital Markets Corp., Attention: Equity Syndicate Department, 3 Times Square, 25th Floor, New York, NY 10036, by telephone at (800) 414-3627 or by e-mail at [email protected]; Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 375 Park Avenue, New York, New York 10152, or by email at [email protected], or by telephone at (800) 326-5897; or UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019, by telephone at (888) 827-7275 or by email at [email protected]. Copies of the preliminary prospectus and, when available, the final prospectus related to the Offering are also available, or will be available, at www.sec.gov.

A registration statement relating to the shares being sold in this offering was declared effective by the Securities and Exchange Commission on October 30, 2019. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

On October 30, 2019 Arcadia Biosciences, Inc. (Nasdaq: RKDA), a leader in science-based approaches to enhancing the quality and nutritional value of crops, reported that it will release its third-quarter 2019 financial and business results after market close on November 6, 2019 (Press release, Arcadia Biosciences, OCT 30, 2019, View Source [SID1234550078]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company has scheduled a conference call for 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss third-quarter results and the quarter’s key strategic achievements. Interested participants can join the conference call using the following numbers:

U.S. Toll-Free Dial-In:

+1-844-243-4690

International Dial-In:

+1-225-283-0138

Passcode:

3489473

A live webcast of the conference call will be available on the Investors section of Arcadia’s website at www.arcadiabio.com. Following completion of the call, a recorded replay will be available on the company’s investor website.

On October 30, 2019 Medigene AG (FSE: MDG1, Prime Standard) reported its participation at the following upcoming scientific and investor conferences (Press release, MediGene, OCT 30, 2019, View Source [SID1234550138]). Medigene’s management and/or scientists will be available for one-on-one meetings at these events.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SITC (Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)) 34th Annual Meeting
Date: 6 – 10 November 2019
Location: National Harbor, USA

BIO Europe
Date: 11 – 13 November 2019
Location: Hamburg, Germany

Jefferies London Healthcare Conference
Date: 20 – 21 November 2019
Location: London, UK

Cell Therapy Manufacturing & Gene Therapy Congress
Date: 3 – 6 December 2019
Location: Amsterdam, Netherlands

61st ASH (Free ASH Whitepaper) Annual Meeting & Exposition
Date: 7 – 10 December 2019
Location: Orlando, USA

ESMO Immuno-Oncology Congress 2019
Date: 11 – 14 December 2019
Location: Geneva, Switzerland

On October 30, 2019 Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, reported Jarrod Longcor, chief business officer of Cellectar, presented a poster highlighting preclinical data with CLR 180099 at the 2019 AACR (Free AACR Whitepaper)-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, being held from October 26– 30, 2019 in Boston, MA (Press release, Cellectar Biosciences, OCT 30, 2019, View Source [SID1234550031]). CLR 180099 is a Phospholipid Drug ConjugateTM (PDC) composed of a uniquely designed phospholipid ether conjugated to a flavagline (FLV) analogue payload.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster, entitled: "CLR 180099, a lipid raft targeted phospholipid-drug conjugate, shows potent improved safety and efficacy against colorectal tumors," highlighted data demonstrating a greater reduction in tumor volume and improved survival with CLR 180099 than docetaxel in a colorectal cancer model. Additionally, as compared to the FLV payload alone, the PDC demonstrated improved tolerability with greater than a 20 fold increase in the maximum tolerated dose. CLR 180099 was also shown to have potent nanomolar activity in other select solid tumorsincluding breast cancer and lung cancer models.

"This new investigational program shows compelling efficacy and safety in these preclinical studies further demonstrating the versatility and potential of PDCs as a new therapeutic class of drugs for cancer," said Jarrod Longcor, chief business officer of Cellectar. "The ability to specifically deliver a variety of oncologic payloads to a broad range of tumor cells emphasizes the PDC technology’s unique and targeted treatment approach. These results further demonstrate this and represent another important advancement in the development and validation of our PDC platform."

About Phospholipid Drug Conjugates

Cellectar’s product candidates are built upon a patented delivery and retention platform that utilizes optimized phospholipid ether-drug conjugates (PDCs) to target cancer cells. The PDC platform selectively delivers diverse oncologic payloads to cancerous cells and cancer stem cells, including hematologic cancers and solid tumors. This selective delivery allows the payloads’ therapeutic window to be modified, which may maintain or enhance drug potency while reducing the number and severity of adverse events. This platform takes advantage of a metabolic pathway utilized by all tumor cell types in all cell cycle stages. Compared with other targeted delivery platforms, the PDC platform’s mechanism of entry does not rely upon specific cell surface epitopes or antigens. In addition, PDCs can be conjugated to molecules in numerous ways, thereby increasing the types of molecules selectively delivered. Cellectar believes the PDC platform holds potential for the discovery and development of the next generation of cancer-targeting agents.